Articles

Masterclass On Site Neuroendocrine Tumours 2020

BJMO - volume 14, issue 4, june 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc, W. Lybaert MD

SUMMARY

On January 30-31st, 2020 the Masterclass on neuroendocrine tumours (NETs) took place in Antwerp, Belgium. This meeting was organised by NETwerk Antwerpen-Waasland (ENETS Centre of Excellence) with support from IPSEN. A broad plethora of presentations on molecular aspects, lung NETs, digestive NETs and neuroendocrine carcinomas (NECs), immunotherapy, Merkel cell carcinoma and patient-centred care were presented. This report will highlight the key messages of the symposium.

(BELG J MED ONCOL 2020;14(4):165–70)

Read more

Journal Scan

BJMO - volume 14, issue 4, june 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc

SUMMARY

In this section of the BJMO, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on oncology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjmo.be) and we will make sure to include it in the journal scan section of the next BJMO issue.

(BELG J MED ONCOL 2020;14(4):159–64)

Read more

Journal Scan

BJMO - volume 14, issue 3, may 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc

SUMMARY

In this section of the BJMO, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on oncology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjmo.be) and we will make sure to include it in the journal scan section of the next BJMO issue.

(BELG J MED ONCOL 2020;14(3):109–13)

Read more

Biomarkers for immune checkpoint inhibition

BJMO - 2020, issue Special, march 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc

Summary

Immune checkpoint inhibitors are effective in restoring the T-cell mediated immune response and can achieve a deep and durable response in a small subset of cancer patients. As only 15% to 25% of the patients with advanced NSCLC will benefit from immunotherapy, a predictive biomarker is required to select patients who will potentially respond. To date, the most intensively studied potential biomarkers consist of the programmed death ligand 1 (PD-L1) expression, the tumour mutational burden (TMB) and the tumour micro-environment (TME), each with its own advantages and challenges. This article will briefly describe each of these biomarkers and will touch upon the relationship between certain genetic modifiers and a response to immunotherapy.

Read more

Journal Scan

BJMO - volume 14, issue 2, march 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc

SUMMARY

The goal of this new section in the BJMO is to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on oncology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please let us know (editor@bjmo.be) and we will make sure to include it in the journal scan section of the next BJMO issue.

(BELG J MED ONCOL 2020;14(2):80–3)

Read more

Immuno-oncology combinations: rationale and clinical implications in melanoma, renal cell carcinoma and lung cancer

BJMO - volume 13, issue 9, february 2019

A. Migeotte , J-F. Baurain MD, PhD, S. Rottey MD, PhD, J. Blokken PhD, PharmD, Tom Feys MBA, MSc

ABSTRACT

Over the past years, immune checkpoint inhibitors have been widely used for the treatment of a broad range of malignancies. Unfortunately, only a proportion of patients derives long-term benefit from these therapeutics. In fact, a majority of patients fails to respond to immune checkpoint inhibition, while others relapse after a certain time. In an attempt to increase the response rate of tumours to these drugs, investigators have looked into the potential of combining different immunotherapeutic agents. Since inhibitors of the immune checkpoints CTLA-4 and PD-(L)1 have different modes of action and given the fact that blocking one of both pathways results in an upregulation of the other, provide a theoretical rationale to combine these agents. This review provides an overview of clinical studies evaluating combinations of CTLA-4 and PD-(L)1 inhibitors in the treatment of melanoma, renal cell carcinoma and non-small-cell lung cancer.

Read more

The 13th Belgian symposium on the integration of molecular biology advances into oncology clinical practice (BSMO/Bordet meeting)

BJMO - volume 14, issue 1, january 2020

J. Blokken PhD, PharmD, Tom Feys MBA, MSc

SUMMARY

On the 22nd and 23rd of November 2019, the Jules Bordet Institute and the Belgian Society of Medical Oncology (BSMO) hosted the 13th Belgian symposium on the integration of molecular biology advances into oncology clinical practice. In the course of the symposium, a fine selection of Belgian and international key opinion leaders discussed the clinical impact of molecular biology advances in a plethora of cancer types.

(BELG J MED ONCOL 2020;14(1):31–41)

Read more
X